ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest adpkd news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks adpkd across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Glasgow-based Mironid closed a €39.9 million ($46 million) Series B round to advance its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Scottish National Investment Bank led the round, joined by Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde.
Summaries by ByteBrief